MASLD的心血管风险:多层面证据揭示
本文批判性评估了代谢功能障碍相关脂肪性肝病(MASLD)与心血管风险关系的流行病学、遗传学、机制及大队列证据。孟德尔随机化与大队列数据提示肝脏脂肪过多本身不独立致动脉粥样硬化,风险由伴随的脂质谱异常介导;现有心血管风险模型未纳入MASLD。临床应使用风险评分充分评估并处理MASLD患者的心血管共病。
要点
- MASLD本身不独立致动脉粥样硬化,风险由脂质异常介导
- 现有心血管风险模型未将MASLD作为独立变量
- 临床应使用风险评分评估并干预MASLD患者心血管风险
核心结论
- 过量肝脏脂肪本身不独立致动脉粥样硬化,观察到的风险由伴随的脂质谱异常介导。
- 现有心血管风险模型均未将MASLD作为独立变量。
- MASLD患者心血管风险高于平均水平且预防治疗常不足,应使用风险评分评估并处理。
研究设计与样本
- 对流行病学、遗传学、机制及大队列证据进行批判性评估。
主要发现
- 许多报告独立关联的研究受样本量小、心血管结局异质、选择与发表偏倚及未充分调整已确立连续心血管危险因素限制。
- 孟德尔随机化与大队列数据提示过量肝脏脂肪本身不独立致动脉粥样硬化。
- 伴随的脂质谱异常介导了观察到的MASLD相关心血管风险。
临床怎么用
- 初级保健医生、肝病科、内分泌科和心脏科医生应使用风险评分充分确定、沟通并处理MASLD患者的心血管及多病共病挑战。
局限性
- 许多报告独立关联的研究存在样本量小、心血管结局异质、选择与发表偏倚及未充分调整已确立连续心血管危险因素等局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with increased cardiovascular risk, yet whether it independently confers risk beyond established cardiometabolic factors remains debated. Herein, we critically appraise epidemiological, genetic, mechanistic, and large-cohort evidence. Many studies reporting independent associations are limited by small sample sizes, heterogeneous cardiovascular outcomes, potential selection and publication bias, and perhaps most importantly, incomplete adjustment for established continuous cardiovascular risk factors. Mendelian randomisation and large-scale cohort data suggest that excess liver fat per se is not independently atherogenic; rather, accompanying abnormalities in lipid profiles mediate the observed risk. Notably, no current cardiovascular risk model includes MASLD as an independent variable. Clinically, MASLD identifies individuals with higher than average cardiovascular risk who are frequently undertreated with preventive therapies. Thus, the priority for primary care physicians, hepatologists, endocrinologists, and cardiologists, among others, should be to adequately determine (using risk scores), communicate on and address the cardiovascular and related multimorbidity challenges inherent in MASLD care.
引用
- Sattar N, Dalakoti M, Alazawi W, et al. Cardiovascular risk in MASLD: What multiple lines of evidence reveal. J Hepatol. 2026. PMID: 41720197. doi:10.1016/j.jhep.2026.02.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。